http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 17:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Replimune+Group%2C+Inc.+++++For%3A+Sep+15/26763257.html si-local-file:///var/storage/secattach/20260713/26763257.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Replimune+Group%2C+Inc.+++++For%3A+Sep+15/26763257.html Mon, 13 Jul 2026 17:20:00 -0400 O.38725784 REPL http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Replimune+Group%2C+Inc.+++++For%3A+Sep+15/26763257.html si-local-file:///var/storage/secattach/20260713/26763257.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Replimune+Group%2C+Inc.+++++For%3A+Sep+15/26763257.html Mon, 13 Jul 2026 17:20:00 -0400 O.38725784 REPL http://www.streetinsider.com/Options/Replimune+%28REPL%29+call+put+ratio+1+call+to+1.3+puts+with+a+focus+on+August+options/26740479.html <p>Replimune (NASDAQ: REPL) 30-day option implied volatility is at 212; compared to its 52-week range of 86 to 402. Call put ratio 1 call to 1.3 puts with a focus on August options. </p> http://www.streetinsider.com/Options/Replimune+%28REPL%29+call+put+ratio+1+call+to+1.3+puts+with+a+focus+on+August+options/26740479.html Tue, 07 Jul 2026 11:08:39 -0400 REPL http://www.streetinsider.com/Upgrades/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html <p>BMO Capital analyst Evan Seigerman upgraded Replimune Group (NASDAQ: REPL) from Market Perform to Outperform with a price target of $16.00.</p><p>The analyst comments "Is the Replimune/FDA chronicle finally reaching a happy ending? Recent news of FDA acceptance of Replimune's re-filed BLA, highlighting the submission as a complete class 1 response, reads positively for the program. This announcement came following a painful saga of two CRLs and numerous fits and starts with the agency over the past almost 12 months. We are upgrading Replimune shares to Outperform from Underperform; with RP1's path to approval now more meaningfully de-risked, we see near-term http://www.streetinsider.com/Upgrades/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html Tue, 30 Jun 2026 04:04:38 -0400 REPL http://www.streetinsider.com/Analyst+Comments/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html <p>BMO Capital analyst Evan Seigerman upgraded Replimune Group (NASDAQ: REPL) from Market Perform to Outperform with a price target of $16.00.</p><p>The analyst comments "Is the Replimune/FDA chronicle finally reaching a happy ending? Recent news of FDA acceptance of Replimune's re-filed BLA, highlighting the submission as a complete class 1 response, reads positively for the program. This announcement came following a painful saga of two CRLs and numerous fits and starts with the agency over the past almost 12 months. We are upgrading Replimune shares to Outperform from Underperform; with RP1's path to approval now more meaningfully de-risked, we see near-term http://www.streetinsider.com/Analyst+Comments/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html Tue, 30 Jun 2026 04:04:38 -0400 REPL http://www.streetinsider.com/Hot+Comments/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html <p>BMO Capital analyst Evan Seigerman upgraded Replimune Group (NASDAQ: REPL) from Market Perform to Outperform with a price target of $16.00.</p><p>The analyst comments "Is the Replimune/FDA chronicle finally reaching a happy ending? Recent news of FDA acceptance of Replimune's re-filed BLA, highlighting the submission as a complete class 1 response, reads positively for the program. This announcement came following a painful saga of two CRLs and numerous fits and starts with the agency over the past almost 12 months. We are upgrading Replimune shares to Outperform from Underperform; with RP1's path to approval now more meaningfully de-risked, we see near-term http://www.streetinsider.com/Hot+Comments/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html Tue, 30 Jun 2026 04:04:38 -0400 REPL http://www.streetinsider.com/Hot+Upgrades/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html <p>BMO Capital analyst Evan Seigerman upgraded Replimune Group (NASDAQ: REPL) from Market Perform to Outperform with a price target of $16.00.</p><p>The analyst comments "Is the Replimune/FDA chronicle finally reaching a happy ending? Recent news of FDA acceptance of Replimune's re-filed BLA, highlighting the submission as a complete class 1 response, reads positively for the program. This announcement came following a painful saga of two CRLs and numerous fits and starts with the agency over the past almost 12 months. We are upgrading Replimune shares to Outperform from Underperform; with RP1's path to approval now more meaningfully de-risked, we see near-term http://www.streetinsider.com/Hot+Upgrades/BMO+Capital+Upgrades+Replimune+Group+%28REPL%29+to+Outperform/26708447.html Tue, 30 Jun 2026 04:04:38 -0400 REPL http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Replimune+Group%2C+Inc.++++++++++++++++/26703089.html si-local-file:///var/storage/secattach/20260629/26703089.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Replimune+Group%2C+Inc.++++++++++++++++/26703089.html Mon, 29 Jun 2026 09:18:00 -0400 O.38725784 REPL http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Replimune+Group%2C+Inc.++++++++++++++++/26703089.html si-local-file:///var/storage/secattach/20260629/26703089.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Replimune+Group%2C+Inc.++++++++++++++++/26703089.html Mon, 29 Jun 2026 09:18:00 -0400 O.38725784 REPL http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Replimune+Group%2C+Inc.+++++For%3A+Mar+31/26702465.html si-local-file:///var/storage/secattach/20260629/26702465.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Replimune+Group%2C+Inc.+++++For%3A+Mar+31/26702465.html Mon, 29 Jun 2026 08:13:00 -0400 O.38725784 REPL http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Replimune+Group%2C+Inc.+++++For%3A+Mar+31/26702465.html si-local-file:///var/storage/secattach/20260629/26702465.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Replimune+Group%2C+Inc.+++++For%3A+Mar+31/26702465.html Mon, 29 Jun 2026 08:13:00 -0400 O.38725784 REPL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Replimune+Group%2C+Inc.+++++For%3A+Jun+29/26702459.html si-local-file:///var/storage/secattach/20260629/26702459.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Replimune+Group%2C+Inc.+++++For%3A+Jun+29/26702459.html Mon, 29 Jun 2026 08:11:00 -0400 O.38725784 REPL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Replimune+Group%2C+Inc.+++++For%3A+Jun+29/26702459.html si-local-file:///var/storage/secattach/20260629/26702459.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Replimune+Group%2C+Inc.+++++For%3A+Jun+29/26702459.html Mon, 29 Jun 2026 08:11:00 -0400 O.38725784 REPL http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Press+Releases/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html <p>WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.</p> <p>The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal http://www.streetinsider.com/Globe+Newswire/Replimune+Reports+Fiscal+Fourth+Quarter+and+Year+End+2026+Financial+Results+and+Provides+Corporate+Update/26702367.html Mon, 29 Jun 2026 08:00:00 -0400 A.06822034 O.20026344 O.38725784 REPL http://www.streetinsider.com/Options/Replimune+%28REPL%29+call+put+ratio+1.6+calls+to+1+put/26701184.html <p>Replimune (NASDAQ: REPL) 30-day option implied volatility is at 145; compared to its 52-week range of 85 to 402. Call put ratio 1.6 calls to 1 put.</p> http://www.streetinsider.com/Options/Replimune+%28REPL%29+call+put+ratio+1.6+calls+to+1+put/26701184.html Mon, 29 Jun 2026 05:56:06 -0400 REPL http://www.streetinsider.com/Upgrades/JPMorgan+Upgrades+Replimune+Group+%28REPL%29+to+Overweight/26697049.html <p>JPMorgan analyst Anupam Rama upgraded Replimune Group (NASDAQ: REPL) from Neutral to Overweight with a price target of $17.00.</p> <p>For an analyst ratings summary and ratings history on Replimune Group <a href="http://www.streetinsider.com/rating_history.php?q=REPL">click here</a>. For more ratings news on Replimune Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=REPL&amp;type=analyst">click here</a>.</p> <p>Shares of Replimune Group closed at $11.13 yesterday.</p> http://www.streetinsider.com/Upgrades/JPMorgan+Upgrades+Replimune+Group+%28REPL%29+to+Overweight/26697049.html Fri, 26 Jun 2026 12:23:10 -0400 REPL http://www.streetinsider.com/Options/Increasing+unusual+put+volume%3A+AS+WEN+REPL+BHC+BTG+IGV+HWM+CHYM+BURL+CIA+/26696207.html <p>Increasing unusual put volume: AS WEN REPL BHC BTG IGV HWM CHYM BURL CIA</p> http://www.streetinsider.com/Options/Increasing+unusual+put+volume%3A+AS+WEN+REPL+BHC+BTG+IGV+HWM+CHYM+BURL+CIA+/26696207.html Fri, 26 Jun 2026 10:32:32 -0400 REPL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Replimune+Group%2C+Inc.+++++For%3A+Jun+26/26695240.html si-local-file:///var/storage/secattach/20260626/26695240.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Replimune+Group%2C+Inc.+++++For%3A+Jun+26/26695240.html Fri, 26 Jun 2026 08:14:00 -0400 O.38725784 REPL